ImmunityBio, Inc.

NASDAQ:IBRX

Biotechnology

Healthcare
$6.70 +2.58%

+$0.18 today

Market cap
$7.13B
Beta
0.10
P/E (TTM)
-8.6
EPS (TTM)
-$0.83
52W Low $1.95High $12.43

Volume 15.77M

Average 16.40M

IBRX Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

ImmunityBio, Inc.NASDAQ: IBRX

Revenue · Q3 FY2026 · quarter ended Sep 2026

Revenue grows, but more slowly than its trailing trend

Q3 FY2026 revenue of $48.84M rose 52.3% year over year, behind the +121.2% change in trailing-twelve-month revenue. Sequentially, it fell 4.7% from the prior quarter. Over 3 fiscal years it compounded at +678.6% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 2 analysts of $200.87M (+77.3%) for the fiscal year ending Dec 2026, a slowdown from the +668.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$48.84M-4.7% QoQ
Last fiscal yearDec 2025
$113.29M+668.3% YoY
LTMSep 2026
$182.57M+121.2% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+52.3%+48.2%-4.2 pp
1 year+668.3%+77.3%-591.0 pp
3-year CAGR+678.6%+93.6%-585.1 pp
5-year CAGR+86.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
113.29M USD
Year-over-year change
+668.3%
4-year CAGR
+231.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How IBRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +121.2% is the 2nd highest of 9, against a peer median of +14.7%.
  • Over three fiscal years its annual growth of +678.6% compares with a peer median of -34.6%.
IBRX Competitors
Revenue for IBRX and competitors
Company Period LTM YoY 3-year CAGR
BNTXBioNTech SELTM Jun 2026€2.64B EUR-8.2%-45.8%
MRNAModerna, Inc.LTM Sep 2026$2.53B USD+13.7%-53.1%
LEGNLegend Biotech CorporationLTM Sep 2026$1.36B USD+49.5%+106.4%
IMCRImmunocore Holdings plcLTM Mar 2026$385.76M USD+15.6%+27.3%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$378.98M USD+51.3%—
IBRXImmunityBio, Inc.LTM Sep 2026$182.57M USD+121.2%+678.6%
VIRVir Biotechnology, Inc.LTM Mar 2026$65.5M USD+214.0%-65.1%
IMTXImmatics N.V.LTM Mar 2026€37.3M EUR-74.1%-34.6%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$23.14M USD-88.4%+23.9%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$0 USD——
NKTXNkarta, Inc.LTM Mar 2026$0 USD——
Peer median (excluding IBRX) —+14.7%-34.6%

Competitors are the stored peer set for IBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue934K240K622K14.75M113.29M
Cost of Revenue0000753K
Gross Profit934K240K622K14.75M112.54M
Gross Margin100.0%100.0%100.0%100.0%99.3%
Research & Development195.96M248.15M232.37M190.14M207.88M
Selling, General & Admin135.26M102.71M129.62M168.78M147.18M
Operating Expenses331.21M351.54M362.87M358.93M368.56M
Depreciation & Amortization14.24M18.26M18.51M17.55M15.53M
EBITDA(320.75M)(351.88M)(478.66M)(264.43M)(223.56M)
EBITDA Margin-34341.8%-146617.1%-76955.5%-1793.4%-197.3%
Operating Income(330.28M)(351.3M)(362.25M)(344.18M)(256.03M)
Operating Margin-35361.9%-146374.2%-58239.5%-2334.2%-226.0%
Interest Income836K2.71M863K2.4M6.7M
Interest Expense14.85M47.15M86.72M131.66M112.53M
Other Income / Expenses(19.56M)(65.99M)(221.64M)(69.46M)(95.58M)
Income Before Tax(349.84M)(417.29M)(583.89M)(413.65M)(351.61M)
Pre-Tax Margin-37456.0%-173869.2%-93873.3%-2805.3%-310.4%
Income Tax Expense9K34K(40K)0(135K)
Net Income(346.79M)(416.57M)(583.2M)(413.56M)(351.4M)
Net Margin-37129.6%-173569.6%-93761.4%-2804.8%-310.2%
EPS (Basic)(0.89)(1.04)(1.15)(0.59)(0.38)
EPS (Diluted)(0.89)(1.04)(1.15)(0.62)(0.38)
Weighted Avg Shares389.23M399.9M508.64M697.31M919.86M
Weighted Avg Shares (Diluted)389.23M399.9M508.64M700.44M919.86M

ImmunityBio, Inc.

NASDAQ:IBRX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.